A Laquière1, C Boustière2, S Leblanc3, G Penaranda4, E Désilets2, F Prat3. 1. Hepato-Gastro-Enterology Department, Saint Joseph Hospital, 26 bd de Louvain, 13008, Marseille, France. alaquiere@hopital-saint-joseph.fr. 2. Hepato-Gastro-Enterology Department, Saint Joseph Hospital, 26 bd de Louvain, 13008, Marseille, France. 3. Gastroenterology Department, Cochin Hospital, Paris, France. 4. Alphabio Biostatistics Lab., European Hospital, Marseille, France.
Abstract
BACKGROUND: Biliary bipolar radiofrequency ablation (RFA) is a new treatment for extrahepatic cholangiocarcinoma (CCA) currently under evaluation. The purpose of this study was to evaluate the safety, particularly biliary fistula occurrence, and the feasibility of biliary RFA in a homogeneous group of patients treated using the same RFA protocol. METHODS: Twelve patients with inoperable or unresectable CCA were included in a bicentric case series study. After removal of biliary plastic stents, a radiofrequency treatment with a new bipolar probe (Habib™ EndoHBP) was applied. The energy was delivered by a RFA generator (VIO 200 D), supplying electrical energy at 350 kHz and 10 W for 90 s. At the end of the procedure, one or more biliary stents were left in place. Adverse events were assessed per-procedure and during follow-up visits. RESULTS: CCA was confirmed in all patients by histology (66%), locoregional evolution or metastatic evolution. The types of CCA were Bismuth I stage (N = 4), Bismuth II stage (N = 3), Bismuth III stage (N = 2) and Bismuth IV stage (N = 3). No serious adverse events occurred within 30 days following endoscopic treatment: One patient had a sepsis due to bacterial translocation on day 1 and another had an acute cholangitis on day 12 due to early stent migration. No immediate or delayed biliary fistula was reported. The ergonomics of the probe made treatment easy in 100 % of cases. Mean survival was 12.3 months. CONCLUSION: Endoscopic radiofrequency treatment of inoperable CCA appears without major risks and is feasible. No major adverse events or biliary fistula were identified.
BACKGROUND: Biliary bipolar radiofrequency ablation (RFA) is a new treatment for extrahepatic cholangiocarcinoma (CCA) currently under evaluation. The purpose of this study was to evaluate the safety, particularly biliary fistula occurrence, and the feasibility of biliary RFA in a homogeneous group of patients treated using the same RFA protocol. METHODS: Twelve patients with inoperable or unresectable CCA were included in a bicentric case series study. After removal of biliary plastic stents, a radiofrequency treatment with a new bipolar probe (Habib™ EndoHBP) was applied. The energy was delivered by a RFA generator (VIO 200 D), supplying electrical energy at 350 kHz and 10 W for 90 s. At the end of the procedure, one or more biliary stents were left in place. Adverse events were assessed per-procedure and during follow-up visits. RESULTS: CCA was confirmed in all patients by histology (66%), locoregional evolution or metastatic evolution. The types of CCA were Bismuth I stage (N = 4), Bismuth II stage (N = 3), Bismuth III stage (N = 2) and Bismuth IV stage (N = 3). No serious adverse events occurred within 30 days following endoscopic treatment: One patient had a sepsis due to bacterial translocation on day 1 and another had an acute cholangitis on day 12 due to early stent migration. No immediate or delayed biliary fistula was reported. The ergonomics of the probe made treatment easy in 100 % of cases. Mean survival was 12.3 months. CONCLUSION: Endoscopic radiofrequency treatment of inoperable CCA appears without major risks and is feasible. No major adverse events or biliary fistula were identified.
Authors: Donald Garrow; Scott Miller; Debajyoti Sinha; Jason Conway; Brenda J Hoffman; Robert H Hawes; Joseph Romagnuolo Journal: Clin Gastroenterol Hepatol Date: 2007-05 Impact factor: 11.382
Authors: M Ducreux; E Van Cutsem; J L Van Laethem; T M Gress; K Jeziorski; P Rougier; T Wagener; O Anak; B Baron; B Nordlinger Journal: Eur J Cancer Date: 2005-02 Impact factor: 9.162
Authors: Emily G Barr Fritcher; Benjamin R Kipp; Kevin C Halling; Trynda N Oberg; Sandra C Bryant; Robert F Tarrell; Gregory J Gores; Michael J Levy; Amy C Clayton; Thomas J Sebo; Lewis R Roberts Journal: Gastroenterology Date: 2009-02-14 Impact factor: 22.682
Authors: Andrea Oliver Tal; Johannes Vermehren; Mireen Friedrich-Rust; Jörg Bojunga; Christoph Sarrazin; Stefan Zeuzem; Jörg Trojan; Jörg Gerhard Albert Journal: World J Gastrointest Endosc Date: 2014-01-16
Authors: Werner Dolak; Florian Schreiber; Hubert Schwaighofer; Michael Gschwantler; Wolfgang Plieschnegger; Alexander Ziachehabi; Andreas Mayer; Ludwig Kramer; Andreas Kopecky; Christiane Schrutka-Kölbl; Gernot Wolkersdörfer; Christian Madl; Frieder Berr; Michael Trauner; Andreas Püspök Journal: Surg Endosc Date: 2013-10-03 Impact factor: 4.584
Authors: Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro Journal: Nat Rev Gastroenterol Hepatol Date: 2016-04-20 Impact factor: 46.802
Authors: Robert J S Coelen; Jantien A Vogel; Laurien G P H Vroomen; Eva Roos; Olivier R C Busch; Otto M van Delden; Foke van Delft; Michal Heger; Jeanin E van Hooft; Geert Kazemier; Heinz-Josef Klümpen; Krijn P van Lienden; Erik A J Rauws; Hester J Scheffer; Henk M Verheul; Jan de Vries; Johanna W Wilmink; Barbara M Zonderhuis; Marc G Besselink; Thomas M van Gulik; Martijn R Meijerink Journal: BMJ Open Date: 2017-09-01 Impact factor: 2.692